8.61
price up icon11.96%   0.92
after-market Dopo l'orario di chiusura: 8.50 -0.11 -1.28%
loading
Precedente Chiudi:
$7.69
Aprire:
$7.57
Volume 24 ore:
1.70M
Relative Volume:
2.13
Capitalizzazione di mercato:
$408.83M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-3.6329
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
+13.89%
1M Prestazione:
+5.64%
6M Prestazione:
-31.56%
1 anno Prestazione:
-28.55%
Intervallo 1D:
Value
$7.48
$8.91
Intervallo di 1 settimana:
Value
$7.31
$8.91
Portata 52W:
Value
$5.35
$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
Nome
Stoke Therapeutics Inc
Name
Telefono
781-430-8200
Name
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Name
Dipendente
128
Name
Cinguettio
@stoketx
Name
Prossima data di guadagno
2025-03-18
Name
Ultimi documenti SEC
Name
STOK's Discussions on Twitter

Confronta STOK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
STOK
Stoke Therapeutics Inc
8.61 408.83M 8.78M -104.70M -82.68M -2.37
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-20 Iniziato Chardan Capital Markets Buy
2024-10-14 Ripresa Leerink Partners Outperform
2024-03-26 Aggiornamento TD Cowen Market Perform → Outperform
2023-11-20 Ripresa JP Morgan Neutral
2023-07-25 Downgrade TD Cowen Outperform → Market Perform
2023-05-01 Aggiornamento BofA Securities Underperform → Neutral
2023-04-26 Ripresa Canaccord Genuity Buy
2023-01-06 Downgrade BofA Securities Buy → Underperform
2022-10-24 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-01-31 Iniziato Jefferies Buy
2021-12-03 Iniziato BofA Securities Buy
2021-11-22 Aggiornamento JP Morgan Neutral → Overweight
2021-05-18 Iniziato UBS Neutral
2021-05-10 Aggiornamento Wedbush Neutral → Outperform
2021-04-26 Ripresa Credit Suisse Outperform
2021-02-10 Downgrade Wedbush Outperform → Neutral
2020-12-15 Ripresa H.C. Wainwright Buy
2020-12-11 Reiterato Needham Buy
2020-10-23 Iniziato Cantor Fitzgerald Overweight
2020-09-29 Ripresa JP Morgan Neutral
2020-09-29 Iniziato Needham Buy
2019-12-18 Iniziato Wedbush Outperform
2019-11-12 Iniziato BTIG Research Buy
2019-10-25 Iniziato H.C. Wainwright Buy
2019-07-15 Iniziato Canaccord Genuity Buy
2019-07-15 Iniziato Cowen Outperform
2019-07-15 Iniziato Credit Suisse Outperform
2019-07-15 Iniziato JP Morgan Overweight
Mostra tutto

Stoke Therapeutics Inc Borsa (STOK) Ultime notizie

pulisher
04:55 AM

Stoke Therapeutics Inc (STOK) rating initates by Chardan Capital Markets - knoxdaily.com

04:55 AM
pulisher
Apr 20, 2025

(STOK) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 17, 2025

Leerink Partnrs Issues Optimistic Estimate for STOK Earnings - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be - simplywall.st

Apr 16, 2025
pulisher
Apr 16, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Analysts - Defense World

Apr 16, 2025
pulisher
Apr 15, 2025

Vanguard Group Inc. Sells 28,049 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Has $1.49 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Makes New Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Needham & Company LLC Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK) - Defense World

Apr 11, 2025
pulisher
Apr 09, 2025

Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK) - The Globe and Mail

Apr 09, 2025
pulisher
Apr 05, 2025

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st

Apr 05, 2025
pulisher
Apr 03, 2025

Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Teacher Retirement System of Texas Purchases Shares of 10,219 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire

Apr 01, 2025
pulisher
Apr 01, 2025

Revolutionary RNA Treatment for Rare Disease: Stoke CEO to Reveal Latest Progress - Stock Titan

Apr 01, 2025
pulisher
Mar 30, 2025

Swiss National Bank Acquires 11,400 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

FY2025 Earnings Forecast for STOK Issued By Chardan Capital - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Charles Schwab Investment Management Inc. Grows Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Dravet Syndrome Market Expected to Experience Major Growth - openPR.com

Mar 26, 2025
pulisher
Mar 25, 2025

Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Mar 25, 2025
pulisher
Mar 25, 2025

(STOK) Technical Data - news.stocktradersdaily.com

Mar 25, 2025
pulisher
Mar 24, 2025

Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter

Mar 23, 2025
pulisher
Mar 22, 2025

Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo

Mar 22, 2025
pulisher
Mar 22, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Brokers Offer Predictions for STOK Q3 Earnings - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

What is Leerink Partnrs’ Forecast for STOK Q1 Earnings? - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Stoke Therapeutics general counsel sells shares totaling $35,731 By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Stoke Therapeutics general counsel sells shares totaling $35,731 - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Analysts Issue Forecasts for STOK Q1 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Stoke therapeutics’ chief medical officer sells $61,238 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Stoke Therapeutics Executives Sell Shares for Tax Liabilities - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 20, 2025

Stoke therapeutics’ chief medical officer sells $61,238 in stock - Investing.com

Mar 20, 2025
pulisher
Mar 19, 2025

The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media

Mar 19, 2025
pulisher
Mar 19, 2025

After Securing Biogen Pact, Stoke’s CEO Edward Kaye Bows Out - insights.citeline.com

Mar 19, 2025
pulisher
Mar 19, 2025

Stoke Therapeutics announces CEO transition - The Pharma Letter

Mar 19, 2025
pulisher
Mar 19, 2025

Stoke Therapeutics Inc (STOK) Q4 Earnings: EPS of -$0.18 Beats E - GuruFocus

Mar 19, 2025
pulisher
Mar 19, 2025

Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Stoke Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals

Mar 18, 2025
pulisher
Mar 18, 2025

Stoke Therapeutics Slips as CEO Steps Down - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

Stoke Therapeutics falls as CEO steps down amid earnings beat By Investing.com - Investing.com Canada

Mar 18, 2025

Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):